|Videos|November 2, 2021

Intersecting Stigma: Rural America, HIV PrEP, and Injection Drug Use

Author(s)Nina Cosdon

Suzan Walters, PhD, discusses her research on the PrEP care continuum among people who inject drugs in rural versus urban settings.

Despite the lifesaving potential of HIV pre-exposure prophylaxis (PrEP), only 1-2% of people who inject drugs (PWID) use it.

The intensely negative stigma surrounding both HIV and injection drug use may be preventing people at high risk for HIV from using PrEP. However, this becomes even more disparate in rural areas, where PWID have little to no knowledge of PrEP and PrEP prescribers are significantly more biased against PWID.

Suzan Walters, PhD, Research Assistant Professor in the NYU School of Global Public Health, affiliated investigator at the Center for Drug Use and HIV/HCV Research, and faculty affiliate at the Center for Opioid Epidemiology and Policy, sat down with Contagion to discuss her recently-published paper, “PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure.”

Walters breaks down the PrEP care continuum, with stages ranging from PrEP awareness, to knowledge, to willingness, to uptake. By examining the PrEP care continuum involvement by rural versus urban setting, Walters identifies disproportionately low PrEP usage and high stigma in rural southern Illinois.

Walters says, “For me, PrEP is just another example of inequity in society.” She was originally motivated to pursue this study topic after the Scott County, Indiana HIV outbreak in 2015, an outbreak attributed to injection drug use that occurred while Walters was working with individuals in syringe service programs.

Walters’s work broadly centers around people who inject drugs and societal inequities in biomedical intervention.

In this first segment of a 2-part interview, Walters introduces her research, the impetus behind the topic, and presents the findings.

You can read Contagion’s original coverage of the study here.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.